Revenue by Product

(Billions of Yen)

  2013 2014 2015 2016 2017
  Sales 401.3 436.9 468.4 472.7 499.3
  Excl.Tamiflu® 390.2 423.8 460.2 459.2 482.4
  Domestic 329.2 349.5 378.0 379.7 388.4
  Oncology 172.4 188.9 215.7 220.3 225.9
  Avastin® 75.4 82.3 93.8 92.1 93.1
  Herceptin® 30.9 31.2 32.7 34.1 33.6
  Rituxan® 26.2 26.2 29.0 32.1 33.4
  Alecensa® - 1.4 8.0 11.9 16.7
  Xeloda® 11.3 10.4 11.1 12.3 12.2
  Perjeta® 2.4 9.1 10.6 11.9 13.6
  Tarceva® 10.4 11.5 11.6 11.5 10.5
  Kadcyla® - 4.0 7.3 8.3 8.0
  Zelboraf® - - 0.5 0.4 0.1
  Alaglio® - - - - 0.0
  Other products 15.7 12.8 11.0 5.8 4.6
  Bone and joint diseases 60.6 69.6 79.4 86.1 93.3
  Actemra® 20.4 24.1 26.8 30.2 33.1
  Edirol® 15.0 19.2 23.1 26.7 29.6
  Bonviva® 0.5 3.4 5.4 7.3 8.7
  Suvenyl® 11.9 10.7 10.5 9.3 8.8
  Other products 12.7 12.3 13.6 12.6 13.1
  Renal diseases 48.9 44.7 45.4 41.1 39.3
  Mircera® 22.5 22.6 23.8 24.2 23.9
  Oxarol® 12.2 12.2 12.9 9.1 8.2
  Other products 14.2 10.0 8.8 7.8 7.2
  Others 47.3 46.4 37.6 32.2 29.9
  CellCept® 7.2 6.5 7.0 7.9 8.9
  Other products 40.1 39.8 30.6 24.3 21.0
  Overseas 61.1 74.3 82.2 79.5 94.0
    Actemra® 43.2 55.7 63.6 60.3 60.9
    To Roche 42.9 55.1 62.6 59.1 59.4
    Neutrogin® 14.7 15.7 14.8 12.2 12.3
    Alecensa® - - 0.5 3.7 13.9
    To Roche - - 0.5 3.7 13.9
    Hemlibra® - - - - 3.1
    Akynzeo® - - 0.0 0.1 0.3
    Aloxi® - - 0.3 0.2 0.1
    Other products 3.1 2.9 3.0 3.0 3.5
  Tamiflu® 11.0 13.0 8.2 13.5 16.9
  Ordinary use 10.1 12.9 8.2 12.0 11.9
  Govt. stockpiles etc. 0.9 0.2 0.0 1.5 5.0
  Royalties and other operating income 22.4 24.2 30.4 19.1 34.9
  Revenues (total) 423.7 461.1 498.8 491.8 534.2
    Domestic 350.8 372.9 390.0 395.1 410.9
    Overseas 72.9 88.2 108.8 96.6 123.3

Sales by Strategic Field (FY2017)

Sales by Strategic Field (FY2017)
  • Amounts are rounded to the nearest 0.1 billion yen.
    Variance and % are calculated based on amounts shown.
    Domestic sales are shown by each disease area.
  • Like
  • Tweet
  • LINE it!
  • E-mail

Financial Results

Back to top